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Objectives: Patients with ulcerative colitis reported that the complexity of the 
treatment regimen, the amount and frequency of administration of the therapy 
are key elements in influencing non-adherence to therapy. MethOds: The objec-
tive of this work was to evaluate the perception of patients with ulcerative coli-
tis compared to adherence to treatment, through a questionnaire distributed by 
clinicians of some Italian hospitals to patients with ulcerative colitis. Results: 
The survey involved 1,064 patients with an average age of 48 years, with a range 
between 5 and 90 years; 46% of the sample is female, 54% are males. More than 50% 
of patients surveyed has a disease duration of less than 10 years and about 35% last 
less than 5 years (median 8 years). There is a prevalence of cases of ulcerative left 
(51%). About 34% reported pancolitis, 14% proctitis and 0.5% chron. The 73% denied 
having adherence issues; the perception of adequate intake of therapy is almost 
complete: only 19% admit to not be adherent. The main reason for non-adherence 
to treatment, regardless of the formulation prescribed, remains forgetfulness (48%), 
followed by the fact of feeling good (20%). In this respect there is a significant differ-
ence depending on whether the disease is in the active phase (47%) or in remission 
(67%). cOnclusiOns: There is a strong adherence by patients, discordant from the 
literature. As regards the reasons for the non-adherence in the low percentage in our 
study, this result appears instead in line with what reported in literature. The direct 
consequence of a failure or suboptimal adherence to treatment involves more than 
the increase in the risk of recurrence of the disease, since patients often interrupt 
chronic medication because they feel good, even a simultaneous increase in costs 
borne by patients and health care system.
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Objectives: The EQ-5D is a standardized, non-disease-specific instrument for 
describing and valuing patients’ health-related quality of life (HRQoL). The aim 
of this study was to measure HRQoL with the use of the EQ-5D and to compare 
it with the self-evaluation of health state in patients with inflammatory bowel 
disease (IBD). MethOds: An online survey was performed. After having given 
informed consent and in order to gain experience with time trade-off (TTO) 
method, patients randomly chose two EQ-5D health states and assigned them 
appropriate utilities. Then, they were asked to assess their own health state by 
the means of EQ-5D, Visual analogue scale (VAS) and TTO. Results: 169 patients 
(76M, 93F) completed EQ-5D, VAS and TTO. Mean age of respondents was 29.9±8.98 
years (range: 18 to 61).73 patients suffered from ulcerative colitis (UC) and 84 from 
Cohn’s disease (CD). In 40 patients the diagnosis was made within one year, 91 
patients were 1-9 years and 38 at least 10 years since diagnosis. 43 patients had 
an operation because of IBD. Respectively, 30, 11, 67, 123 and 117 patients had at 
least moderate deterioration in domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Mean EQ-5D value (using Polish TTO norms) 
was 0.829±0.162 and mean VAS score was 64.23±21.17. There was a significant 
correlation between EQ-5D and self-evaluation of health state (mean value 0.83, 
r= 0.279, p< 0.001). There was no statistically significant difference in any of the 
subgroup analyses in any of the subgroup analyses (CD vs. UC: 0.821 vs. 0.839, ≤ 1 
year vs. 1-9 years vs. ≥ 10 years from diagnosis: 0.827 vs. 0.815 vs. 0.866, operation 
vs. only conservative treatment: 0.823 vs. 0.831, p> 0.05). cOnclusiOns: EQ-5D 
appeared valid and informative in Polish IBD patients. However, it seems not to be 
sensitive enough to distinguish between different subgroups in this heterogeneous 
population.
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Objectives: In order to make decisions experts and patients have to face trade-
offs between benefit and harms. Harms can be expressed as the risk of occurrences 
and also the severity. Ideally a combination of both should be taken into account 
when making decisions. In the context of approval, allocation decisions and benefit 
assessment, the question arises as risk and severity of side-effects are included in 
the decision making process. MethOds: The discrete choice experiment used com-
pound side-effect attributes of a hepatitis C treatment by combining severity and 
risk. Thus, patients’ preferences regarding the probability of occurrence and severity 
of side-effects could be measured. The decision model included sustained-virologi-
cal-response, duration of therapy and number of interferon injections and five com-
pound side-effect attributes: rash, anemia, nausea/diarrhea, tiredness/fatigue and 
headache. The compound attribute were composed out of risk and severity, resulting 
in 6 levels per attribute. The experimental design (3*3+5*6) (Ngene) consisted of 
72choices, which were divided into 6 blocks. Results: N= 561 hepatitis C-patients 
(58.1%male) participated in computer-assisted personal interviews. Within the 
random parameter logit model (95%CI) the preference analysis could show that 
participants valued severity and risk of side-effects differently. The analysis of the 
six levels e.g. for the side-effect “anemia” was weighted the following: coef.“mild 
(NMA) has evaluated the relative efficacy of ciclosporin, prolonged-release (PR) 
and immediate-release (IR) tacrolimus in adult liver transplant recipients based on 
randomized controlled trials and large observational studies published since 2000. 
Based on the NMA findings, the present study evaluated the cost-utility of using 
PR tacrolimus relative to ciclosporin or IR tacrolimus in liver transplant recipi-
ents in the UK setting. MethOds: A Markov model was developed in Microsoft 
Excel to evaluate the cost-effectiveness of immunosuppressive regimens in liver 
transplant recipients. The model captured costs associated with immunosup-
pression, retransplantation and acute rejection (AR). Mortality, graft loss and 
AR odds ratios were derived from the NMA. Costs were taken from the British 
National Formulary and the NHS National Tariff and expressed in 2014 pounds 
sterling. Future costs and effects were discounted at 3.5% annually. Results: Over 
a 25-year time horizon, PR tacrolimus resulted in increased life expectancy and 
quality-adjusted life expectancy (QALE) relative to IR tacrolimus and ciclosporin. 
Relative to ciclosporin, QALE increased by 1.17 quality-adjusted life years (QALYs) 
with PR tacrolimus while costs increased by GBP 18,107, yielding an incremen-
tal cost-effectiveness ratio (ICER) of GBP 15,443 per QALY gained. Relative to IR 
tacrolimus, QALE increased by 0.78 QALYs and costs by GBP 1,646, resulting in an 
ICER of GBP 1,646 per QALY gained. Sensitivity analysis showed the analysis to be 
most sensitive to the dosing assumptions. cOnclusiOns: Based on a UK-specific 
analysis of the projected cost and effectiveness of PR tacrolimus relative to IR 
tacrolimus and ciclosporin, PR tacrolimus improved life expectancy and quality-
adjusted life expectancy relative to both IR tacrolimus and ciclosporin. While 
costs of PR tacrolimus were higher, the incremental cost-effectiveness ratios fell 
below GBP 20,000.
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Objectives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α 550mg is effective in reducing the recurrence of overt HE 
episodes, and hospital utilisation. We characterised the cost effectiveness includ-
ing societal impact of rifaximin-α 550mg plus a standard of care (SOC) versus SOC 
alone (lactulose) in patients with liver cirrhosis in The Netherlands. MethOds: A 
Markov state transition model was used. Outcome metrics were incremental cost 
effectiveness ratios (ICERs), derived from cost/quality adjusted life years (QALYs) 
estimates and estimates of impact of work productivity loss upon patient/carer 
using a friction cost method reflecting patient and societal considerations in the 
model. Outcomes data were from two trials of rifaximin-α 550mg. Dutch costs data 
(2010) were derived from published sources and societal cost estimates were from 
the Dutch costing manual (2010) inflated to 2015 prices. Health-related utility was 
estimated indirectly from disease-specific quality of life RCT data. The time horizon 
was five years. Costs and benefits were discounted at 4% and 1.5%, respectively. Real 
world data were applied into the model for length of hospital stay and number of 
admissions. Results: 5 year average costs of included care/societal elements was 
€ 88,386 in the rifaximin-α 550mg + SOC arm and € 82,968 in the SOC arm, a € 5,418 
difference. Corresponding values for benefits were 2.45 and 1.89 QALYs/person, 
respectively, a difference of 0.56 QALYs over five years. This translated into a cost 
effective base-case ICER of € 9,576 at a five year time horizon. cOnclusiOns: Use 
of rifaximin-α 550 mg + SOC in patients with recurrent HE in the context of liver 
cirrhosis represented good value and was cost-effective compared with SOC alone, 
by reducing overt HE episodes, the likelihood of hospital admission and hospital 
length of stay.
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Objectives: Hepatitis B infection is the major cause of chronic liver disease in 
Iran.This study has been designed to evaluate the cost-effectiveness of different 
options of medication therapy for CHB in Iran. MethOds: An economic evaluation 
of cost-utility was conducted to assess five oral medication strategies including: 
Adefovir, Lamivudine, Adefovir + Lamivudine, Entecavir, and Tenofovir. A Markov 
micro-simulation model was used to estimate the clinical and economic out-
comes in a life time horizon and based on a societal perspective. Medical and 
non-medical direct costs and indirect costs were included in the study and Life-
Years Gained (LYG) and Quality-Adjusted Life-Years (QALY) were determined as 
the measures of effectiveness. The results were presented in terms of Incremental 
Cost Effectiveness Ratio (ICER) per QALY or LYG. The model was consisted of nine 
states of the disease; the transition probabilities for the movement between the 
states were obtained using clinical evidences and expert opinions collected from 
all over the world. Probabilistic sensitivity analyses (PSA) was used to measure 
the effects of uncertainty in model parameters. Results: Results found that 
the Tenofovir treatment strategy was more effective and less costly than other 
options. In addition, Tenofovir had the highest QALY and LYG for the HBeAg -ve 
and HBeAg +ve with 13.52 and 15.21; 2133 and 21.53 (discounted) in all compari-
sons, respectively. Also, PSA proved the robustness of the model results. So that, 
The cost-effectiveness acceptability curves showed that TDF was the most cost-
effective treatment in 86.1% and 87.7% of the simulations for the HBeAg -ve and 
HBeAg +ve with WTP thresholds less than PPP $ 45270 (maximum WTP per QALY), 
respectively. cOnclusiOns: The results showed that using Tenofovir in patients 
with CHB was a highly cost-effective strategy.
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MethOds: Translatability assessments of the US English version of the IBS-D 
PRO were performed by experienced PRO translators who were native speakers 
of each target language and currently residing in-country. Languages included: 
Chinese (China); Dutch (Netherlands); French (Belgium); German (Germany); 
Japanese (Japan); Polish (Poland); Portuguese (Brazil); Russian (Russia); Spanish 
(Mexico); and Spanish (US). The project team assessed the instrument to identify 
potential linguistic and/or cultural adaptation issues. After the identified issues 
were resolved, the instrument was translated into Spanish (US) and Japanese 
through a process of two forward translations, one reconciled translation, and 
one back translation. The project team reviewed the translated versions before 
the instruments were evaluated by cognitive debriefing interviews (CDIs) with 
samples of five Spanish (US) and five Japanese IBS-D patients. Results: A few 
linguistic and cultural adaptation concerns were identified during the translat-
ability assessment as requiring minor revisions: mainly the presentation of dates/
times and word structure. During the CDIs, two out of five Spanish respondents 
misunderstood the term “bowel movement” to mean only diarrhea in the Spanish 
version. Consequently, the term was changed from “movimiento intestinal” to 
“evacuaciones.” None of the Japanese respondents identified issues with the 
Japanese version. cOnclusiOns: The translatability of the IBS-D PRO instru-
ment into ten target languages was confirmed, with only minor changes made to 
the translations of the instrument. The translation and linguistic validation into 
Spanish (US) and Japanese provide evidence that this instrument can be used in 
multinational trials and clinical settings.
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Objectives: The haemorrhoidal disease is a frequent and chronic illness. The 
anal fissure is the second reason of proctologic medical visits. At the moment, 
there is only a clinical score measuring the grade of the haemorrhoids, but the 
impact of the disease on the patients’ quality of life is not evaluated. The objec-
tive of this study is to validate a specific questionnaire to evaluate the burden 
of the haemorrhoidal disease and anal fissure (HEMO-FISS) on the patients’ daily 
life. MethOds: The questionnaire HEMO-FISS, including 38 questions, has been 
submitted to patients suffering from a haemorrhoidal disease or an anal fissure and, 
consulting a participating proctologist in France during the study period (2012-2014). 
The psychometric properties were evaluated by testing the acceptability, construct 
validity and reliability. A principal component analysis (PCA) using Varimax rota-
tion, a Spearman correlation coefficient with SF-12 and PGWBI and a multi-trait 
analysis (MTA) were conducted to assess the construct validity of the questionnaire. 
The reliability was evaluated using Cronbach’s alpha coefficient (CAC). Backward 
Cronbach alpha curves (BCAC) were drawn. Results: A total of 256 patients were 
included in the study. Following the factor analysis, four dimensions were defined: 
physical disorders, psychology, troubles defecating and sexuality. The number of 
questions was reduced from 38 to 28. Item reduction was based on MTA and BCAC. 
A strong correlation was observed between SF-12 and the dimensions regarding 
physical disorders (with PCS) and psychology (with MCS). The Cronbach’s coef-
ficient (all > 0.7) reflected a good internal consistency of the different dimensions 
of the questionnaire. cOnclusiOns: The questionnaire HEMO-FISS displays good 
properties to evaluate the burden of haemorrhoids and anal fissures. Consecutive 
to this preliminary validation, a graded response model (GRM) will be developed to 
precise the unidimensionality of each dimensions.
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Objectives: The study focused on a secondary aspect of liver diseases, never 
investigated in Italy so far. The study purpose was in fact to obtain the patients’ 
perception about the role of nutrition during the disease phases and in general for 
liver welfare, with the final aim of understanding the importance given to nutri-
tion by patients and the current disinformation to be possibly tackled. MethOds: 
EpaC is the most important Italian NGO for hepatopathic patients. An anonymous 
web-based questionnaire was published on the association website www.epac.it. 
It was composed of multiple choice and open questions investigating the gen-
eral info of the patient, health state, and opinions/perceptions about nutritional 
aspects. Results: 483 patients participated the survey. The profile of participants 
was assessed concerning sex, age, health condition, presence of cirrhosis. Mean age 
was 52.9 (min 24 – max 80), 60% males, 76% HCV-positive, 15% cirrhotic. 99% know 
alcohol can damage the liver and 86% answered that any alcohol quantity is poten-
tially harmful (79% do not assume alcohol and 62% go on after being cured). Besides 
alcohol, other foods believed to be harmful to liver are all fried foods, salami, sugar 
and sweets, meat (in particular red meat), cheeses (above all fat cheeses). Although 
in low percentages, 5% and 13% respectively consider vegetables and fruit as harm-
ful. Moreover, 53% think a vegan/vegetarian diet is essential, but 81% would like to 
have a specialist nutritional advice. cOnclusiOns: Considering that nutritional 
aspects are important in everybody’s life, they are particularly relevant in case of 
liver disease. The results shown express patients’ degree of knowledge about these 
aspects and highlights that a certain disinformation is widespread. The results 
also point out liver-suffering patients’ need to receive clinicians’ evidence-based 
advice/information on nutrition and lifestyle as part of the routine counselling 
and to develop an educational campaign on nutrition for hepatopathic patients.
severity*10%risk”:0.355; coef.“moderate severity *10% risk”:0.112; coef.“severe sever-
ity *10% risk”:-0.246; coef.“mild severity *40% risk”: 0.165; coef.”moderate severity 
*40% risk”:-0.116; coef.“severe severity *40% risk”: -0.271. cOnclusiOns: The DCE 
could prove that the included hepatitis C patients have different preferences with 
respect to the probability of risk relative to the severity of different side-effects. In 
all significant characteristics the dominance for less severity and less risk could be 
proven and both aspects were taken into account when making treatment decisions. 
For the first time compound side-effect attributes have been applied in a preference 
elicitation method and detected corresponding differences within patient prefer-
ence measures.
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Objectives: Ulcerative colitis (UC) management aims to reduce symptoms 
associated with the disorder as well as inducing and maintaining remission. 
Surgery is typically considered in severe or refractory UC patients who have not 
responded to maximal treatment. This study evaluated HRQL following surgery, 
along with experience and severity of complications, including those experienced 
in the longer-term. MethOds: UK adult UC patients (n= 202) who had undergone 
bowel surgery completed an online survey including EQ-5D-5L utility assessment, 
Work Productivity and Activity Impairment (WPAI), Inflammatory Bowel Disease 
Questionnaire (IBDQ), post-surgical complications, and Female Sexual Function 
Index (FSFI) or International Index of Erectile Function (IIEF). Results: Over 58% 
of participants were > 1 year post-surgery. Mean EQ-5D utility for the overall sample 
was 0.74. Mean utility was significantly higher in those who reported no complica-
tions post-surgery than in those who did (0.90 vs 0.71; p< 0.001). The most commonly 
reported symptoms since surgery were increased fatigue (56%), abdominal pain 
(42%), and increased stool frequency (31%). Participants with complications had 
reduced HRQL across bowel symptoms, systemic symptoms, emotional functioning 
and social functioning IBDQ domains. They also reported more work time missed, 
greater impairment while working and greater overall impairment of regular activi-
ties due to UC than those without complications. Of those responding about sexual 
function, FSFI scores for 68% of female participants indicated sexual dysfunction 
and IIEF scores for 52% of male participants indicated at least mild erectile dysfunc-
tion. A marked decrease in utility by IBDQ disease severity was observed: those 
classified as having severe disease had lower scores than those classified as being 
in remission (0.52 vs 0.88). cOnclusiOns: Although surgery for UC is intended 
to be curative, IBDQ and EQ-5D data suggest that HRQL may not return to normal 
levels. These results may be related to severity of ongoing fatigue, bowel and sexual 
function problems.
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Objectives: Short bowel syndrome (SBS) is a rare, complex clinical condition that 
results from loss of intestinal absorptive capacity. Parenteral nutrition (PN) is often 
needed to maintain clinical status in patients with SBS. Teduglutide reduces, and 
in some cases eliminates, patients’ dependency on PN. PN is not exclusively used 
in patients with SBS and, since robust utility data is often difficult to collect for rare 
conditions due to limited patient numbers, a wider body of published literature 
reporting a link between PN and health-related quality of life (HRQL) was consid-
ered. We assessed if an acceptable body of evidence was available to determine the 
HRQL impact associated with the use of PN that could support an assessment of 
the potential impact of reduced PN using teduglutide. MethOds: Searches were 
performed using MEDLINE, MEDLINE In-Process and Cochrane Library. Additionally, 
hand searches were performed at targeted conferences. Of 2,724 studies screened, 
76 met the inclusion criteria: adults receiving PN for longer than 6 months and 
reported utilities or other HRQL data. Results: Patients receiving PN were shown 
to have lower HRQL than the general population. HRQL was shown to increase 
at initiation of PN, compared to the pre-PN state. However, discontinuation of PN 
and intestinal transplantation (ITx) were associated with further improvements in 
HRQL. Trends associating increased number of PN complications, PN volume and 
PN frequency with lower HRQL were also identified. cOnclusiOns: Improvements 
in HRQL achieved by discontinuing PN and ITx suggest that weaning patients with 
SBS off PN could increase HRQL. These, along with results of an ongoing vignette 
study in patients with SBS, may allow quantification of the HRQL associated with 
the use of teduglutide in SBS.
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Objectives: Following the 2009 FDA Guidance, a new PRO instrument was devel-
oped to support endpoints in multinational clinical trials assessing IBS with diar-
rhea (IBS-D) symptom severity. Our objective was to assess the translatability of 
the IBS-D PRO instrument into ten languages, and subsequently perform a cultural 
adaptation/linguistic validation of the questionnaire into US Spanish and Japanese.] 
